Endoscopic local injection of a new drug delivery formulation, anticancer drug bound to carbon particles, for digestive cancers: Pilot study
- 76 Downloads
A new dosage formulation consisting of an anticancer drug bound to activated carbon particles was developed for the treatment of digestive cancer in patients in whom operation is contraindicated. The new formulation is designed to distribute higher levels of anticancer drug to the regional lymph nodes and at the injection site compared to distribution of the drug in aqueous solution. In 12 patients with histologically proven carcinoma (7 with superficial esophageal cancer and 5 with early or proper muscle layer-infiltrating gastric cancer), an anticancer drug bound to carbon particles (total dose, 40–100mg peplomycin or 250–500mg methotrexate per person) was injected endoscopically into the primary lesions. Eleven of the 12 patients are currently alive, 12–64 months after therapy, or they died without evidence of cancer 12–98 months after the treatment. One patient has remained cancer-free for 32 months after a second course of the new formulation therapy given to treat a recurrence detected 26 months after the first treatment. Endoscopic injection of this new dosage formulation seems to control these digestive cancers in patients in whom operation is contraindicated.
Key wordsclinical trial anticancer drug activated carbon particles digestive cancers lymph node metastasis endoscopy
Unable to display preview. Download preview PDF.
- 2.Ide H. Surgical treatment of superficial esophageal cancer (in Japanese with English abstract). Rinshou Kyoubu-Geka (J Ann Thorac Surg) 1991;11:191–197.Google Scholar
- 5.Makuuchi H, Machimura T, Soh Y, et al. Endoscopic mucosectomy for mucosal carcinomas in the esophagus. Jpn J Gastroenterol Surg 1991;24:2599–2603.Google Scholar
- 7.Takemoto T, Yanai H, Tada M, et al. Evaluation of endoscopic resection for early gastric cancer (in Japanese with English abstract). Stomach and Intestine 1991;26:365–370.Google Scholar
- 11.Hagiwara A, Takahashi T, Ueda T, et al. Activated carbon particles as anticancer drug carrier into regional lymph nodes. Anti-Cancer Drug Des 1987;1:313–321.Google Scholar
- 16.Matsuda A, Yoshioka O, Yamashita T, et al. Fundamental and clinical studies on new bleomycin analogues. Recent Results in Cancer Research “Antitumor Antibiotics” 1978;63:191–210.Google Scholar
- 17.Japanese classification of gastric carcinoma. Japanese Research Society for Gastric Cancer. First English edition. Tokyo: Kanehara, 1995.Google Scholar
- 18.Rusznyak I, Foldi M, Szabo G. Absorption into lymph capillaries. In: Youlten L (ed) Lymphatics and lymph circulation; physiology and pathology. 2nd ed. London: Pergamon, 1967;418–474.Google Scholar
- 21.Terashima T, Umezawa H. Lethal effect of bleomycin on cultured mammalian cells. J Antibiotics 1970;23:300–304.Google Scholar
- 26.Hagiwara A, Takahashi T, Ueda T, et al. Reduced pulmonary toxicity of peplomycin in a new drug-delivery system. Anti-Cancer Drug Des 1988;2:319–324.Google Scholar
- 28.Hagiwara A, Takahashi T, Sawai K, et al. Endoscopic injection of methotrexate bound to activated carbon particles. In: Proceedings of 1st International Gastric Cancer Congress. Bologna: Monduzzi Editore, 1995:1643–1646.Google Scholar
- 29.Japanese Society for Esophageal Diseases. Guidelines for the clinical and pathologic studies on carcinoma of the esophagus. 8th ed. Tokyo: Kanehara, 1992.Google Scholar